Literature DB >> 15823767

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

James K Malone1, Lisa F Kerr, Barbara N Campaigne, Richard A Sachson, John H Holcombe.   

Abstract

OBJECTIVE: This study aimed to assess glycemic response to a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro (Mix 75/25) BID plus metformin versus insulin glargine QD plus metformin in patients with type 2 diabetes mellitus (DM).
METHODS: Adults new to insulin therapy were enrolled in a multicenter, randomized, prospective, open-label, crossover study with 16 weeks on each treatment. Variables included glycosylated hemoglobin (HbA(1c)), hypoglycemia rate, fasting blood glucose (FBG), 2-hour postprandial blood glucose (ppBG), and rise in blood glucose after meals.
RESULTS: One hundred five patients (mean age, 55 years) were randomized. There was no difference in baseline mean values for either treatment sequence group for body mass index, duration of DM, or HbA(1c). Ninety-five patients completed the study and 67 were included in the efficacy analysis. Mix 75/25 was associated with lower mean (SD) HbA(1c) at end point (7.4% [1.1%] vs 7.8% [1.1%]; P = 0.002). More patients using Mix 75/25 achieved target HbA(1c) < or =7.0% (42% [30/71] vs 18% [13/71]; P < 0.001). With Mix 75/25, the mean (SD) 2-hour ppBG was similar after lunch but lower after breakfast (156.4 [43.6] vs 171.1 [44.9] mg/dL; P = 0.012) and dinner (164.8 [42.5] mg/dL vs 193.8 [51.0] mg/dL; P < 0.001), although FBG was higher (139.3 [36.6] mg/dL vs 123.9 [34.9] mg/dL; P < 0.001). Rise in ppBG was lower with Mix 75/25 after breakfast (16.9 [47.0] mg/dL vs 47.4 [34.8] mg/dL; P < 0.001) and dinner (14.2 [44.1] mg/dL vs 45.9 [41.3] mg/dL; P < 0.001). Gain in mean (SD) body weight was greater with Mix 75/25 than insulin glargine (2.3 [4.0] kg vs 1.6 [4.0] kg; P = 0.006). For all randomized patients, mean (SD) hypoglycemia rates were lower with insulin glargine (0.68 [1.38] vs 0.39 [1.24] episodes/patient per 30 days; P = 0.041), although nocturnal hypoglycemia was similar.
CONCLUSION: In this study population, Mix 75/25 plus metformin was associated with lower HbA(1c) than insulin glargine plus metformin, smaller rise in ppBG after breakfast and dinner, and higher proportion of patients achieving HbA(1c) < or =7.0%, with a slight increase in overall (but not nocturnal) hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15823767     DOI: 10.1016/j.clinthera.2004.12.015

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  37 in total

Review 1.  Special considerations with insulin therapy in older adults with diabetes mellitus.

Authors:  Arshag D Mooradian
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

Review 2.  Using insulin in type 2 diabetes: in need of a renaissance?

Authors:  David Kerr; Tolulope Olateju
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

Review 3.  Basal insulin treatment in type 2 diabetes.

Authors:  Maka S Hedrington; Lindsay Pulliam; Stephen N Davis
Journal:  Diabetes Technol Ther       Date:  2011-06       Impact factor: 6.118

Review 4.  Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes.

Authors:  Josep Vidal
Journal:  Eur Endocrinol       Date:  2013-08-23

Review 5.  Premixed insulin analogues for the treatment of diabetes mellitus.

Authors:  Alan J Garber
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes.

Authors:  Philip Levy
Journal:  MedGenMed       Date:  2007-04-16

7.  The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes.

Authors:  Jessie Fahrbach; Scott Jacober; Honghua Jiang; Sherry Martin
Journal:  J Diabetes Sci Technol       Date:  2008-09

8.  Starting insulin in type 2 diabetes: Overcoming barriers to insulin therapy.

Authors:  Udaya M Kabadi
Journal:  Int J Diabetes Dev Ctries       Date:  2008-04

9.  Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.

Authors:  J Gumprecht; M Benroubi; V Borzi; R Kawamori; J Shaban; S Shah; M Shestakova; Y Wenying; R Ligthelm; P Valensi
Journal:  Int J Clin Pract       Date:  2009-06       Impact factor: 2.503

Review 10.  Insulin therapy for type 2 diabetes.

Authors:  Sanne G Swinnen; Joost B Hoekstra; J Hans DeVries
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.